EuroPCR 2021 Wrap-up: Mitral and Tricuspid Therapies

Published: 20 May 2021

  • Views:

    Views Icon 11168
  • Likes:

    Heart Icon 7

Overview

Full programme

Part 3 of 3

PART 3: EuroPCR 2021 Wrap-up: Treating TR with the Edwards Portfolio

Nicolas M Van Mieghem, Philipp Lurz, Philip Raake

Overview

This timely programme brings together leading physicians ideally placed to provide update and definitive comment on the latest developments within the Edwards mitral and tricuspid space. Programme Chair Prof Nicolas van Mieghem (Erasmus University, The Netherlands) is joined by Prof Philipp Lurz (Heart Center Leipzig, Germany) and Prof Philip Raake (Heidelberg University Hospital, Germany) as they explore EuroPCR 2021 highlights in this field, addressing pivotal studies, early feasibility studies and the latest real-world data.

 

In Part 2 of this three-part series, the faculty address the PASCAL platform for MR, introduce the new PASCAL Stabilizer Rail System, and examine sustained MR reduction supported by the results of the CLASP study, 2 year follow-up data. In addition, real-world PASCAL Platform, including PASCAL Ace, MR experience from Bad Neustadt, Munich and Barcelona is discussed.

 

In Part 3, with the focus on TR, the faculty consider the complexities and challenges of the Tricuspid valve compared to the Mitral valve, review the PASCAL platform for TR and CLASP TR EFS data at six months follow-up, the commercial results of the PASCAL Repair System, and single centre experiences. The discussions then centre upon the Cardioband Tricuspid System, its new features and outcome data in the TriBand registry, and finally the EVOQUE Tricuspid Valve Replacement System, focusing on the TRISCEND Study data.

 

For more information from Edwards Lifesciences at EuroPCR2021 – including expert interviews and tools and techniques – please click here to visit the TMTT Hub.

 

This wrap-up is supported by Edwards Lifesciences

More from this programme

Part 1

PART 1: EuroPCR 2021 Wrap-up: Mitral and Tricuspid Therapies – An Introduction

Prof Nicolas van Mieghem is joined by Prof Philipp Lurz and Prof Philip Raake to provide a brief introduction to developments at EuroPCR 2021 in the fields of MR and TR, including key highlights from late breakers, abstracts and expert insight sessions.

Part 2

PART 2: EuroPCR 2021 Wrap-up: Mitral Valve Repair with the PASCAL Platform

The faculty present the latest developments in MR therapies, and address key questions including 'how important is the durability of MR reduction?', and 'what are the key differentiators of the PASCAL technology that support superior real-world evidence outcomes in MR patients?'. The faculty also examine key takeaways from real-world experience data outcomes with PASCAL and PASCAL Ace.

Part 3

PART 3: EuroPCR 2021 Wrap-up: Treating TR with the Edwards Portfolio

In this part, the faculty review the key differentiators of the PASCAL TR technology that help underpin the excellent CLASP TR EFS 6mo results (Late Breaking Trial at EuroPCR) and real-world evidence outcomes in TR patients. Discussions also cover the learning curve with the PASCAL platform in TR, and address the promise of EVOQUE for the treatment of TR, in addition to reviewing real-world experience of the Cardioband Tricuspid System.

Faculty Biographies

Nicolas M Van Mieghem

Nicolas M Van Mieghem

Medical Director

Personal History

From an early age, Professor Nicolas Maria Van Mieghem decided to pursue a career that would help others. “I enjoy the feeling of being able to help someone or do something important for them. I wanted to enter a profession that would channel my energy— I was always a busy child,” he says. 

A budding athlete, he was a member of Belgium’s national swimming team but soon realized that medicine was his true calling. His father was a general cardiologist and one of his biggest influences early in his career.

Professor Van Mieghem initially intended to train as a cardiac surgeon but decided to specialise in interventional cardiology instead, following advice from a mentor. This decision was cemented when he read the first-in-human case report of transcatheter aortic valve implantation (TAVI) in Circulation by Alain Cribier in 2002. 

His mantra is mens sana in corpore sano (a…

View full profile
Philipp Lurz

Philipp Lurz

Prof Philipp Lurz is Deputy Head of the Department at Heart Center Leipzig, Germany, a position he has held since 2018. Previously, Prof Lurz was a Clinical Research Fellow at Great Ormond Street Hospital for Children NHS Foundation Trust. He completed his education at the University of Leipzig, and is a member of the German Society of Cardiology. Prof Lurz is widely published in leading international peer-reviewed journals.

View full profile
Philip Raake

Philip Raake

Head, HFU Centre, Department of Cardiology, Heidelberg University Hospital, Germany

Prof Philip Raake is a senior physician who leads the HFU centre at the Department of Cardiology at Heidelberg University Hospital. He also runs the Interventional HF programme.

Prof Philip Raake attended medical school at the Ludwig-Maximilians University in Munich. Between 2006 and 2008, Prof Raake worked at the Center for Translational Medicine, under the direction of Prof Walter Koch, at the Thomas Jefferson University, Philadelphia.

In 2008 Prof Raake returned to Germany, where his established the first university Advanced Heart Failure Unit in Germany focusing on optimised care in advanced HF. He has authored or co-authored several papers in leading peer-reviewed journals on HF basic molecular mechanisms, and clinical aspects of advanced HF. He serves on several working groups for the German Society for Cardiology and the German Federal Physicians Association.

View full profile